Original Research

DOI: 10.4244/EIJ-D-25-00349

A preclinical study of combined hepatic and renal artery denervation

Felix Mahfoud1, MD; Stefan Tunev2, DVM; David E. Kandzari3, MD; Eric A. Secemsky4, MD; Pam R. Taub5, MD; Raven A. Voora6, MD; Lucas Lauder1, MD; Cian Ryan2, BEng; Julie Trudel2, PhD; Douglas A. Hettrick2, PhD; Markus Schlaich7, MD

Abstract

Background: Overactivity of the hepatic and renal sympathetic nerves is associated with chronic cardiovascular and metabolic conditions, including hypertension.

Aims: We studied the effect of combined renal and hepatic denervation through treatment of the common hepatic artery and the renal arteries.

Methods: Denervation was performed in the common hepatic artery and both renal arteries and their major branch vessels in normotensive swine using the same multielectrode radiofrequency (RF) ablation catheter (Symplicity Spyral). Renal and liver tissue samples were obtained for histological examination in two cohorts at 7 and 28 days post-procedure (n=5 sham, n=10 denervation for each timepoint).

Results: Combined hepatic and renal denervation was successfully achieved in all animals. At 7 days, the mean lesion depth was 5.8±1.4 mm in the renal arteries and 4.7±0.7 mm in the hepatic artery. Compared with controls, the mean renal cortical norepinephrine (NE) levels were reduced by 88.2% in the 7-day model and by 84.5% in the 28-day model. Liver NE decreased by 94.6% at 7 days and by 91.1% at 28 days (p<0.0001 for all comparisons with baseline). No inadvertent injury was detected in the treated arteries or adjacent tissues.

Conclusions: Combined hepatic and renal denervation using the same multielectrode RF denervation system resulted in a substantial reduction in both renal and hepatic tissue NE levels that was sustained up to 28 days without collateral tissue injury. These mechanistic findings may have implications for the treatment of chronic diseases impacted by hepatic and renal sympathetic nervous system overactivity.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 17
Sep 1, 2025
Volume 21 Number 17
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV9I1A19 May 21, 2013
A novel non-vascular system to treat resistant hypertension
Heuser R et al
free

CLINICAL RESEARCH

10.4244/EIJV11I1A18 May 19, 2015
Symplicity multi-electrode radiofrequency renal denervation system feasibility study
Whitbourn R et al
free

10.4244/EIJV9SRA26 May 21, 2013
Potential new indications and future studies
Sudano I et al
free

10.4244/EIJV14I12A225 Dec 20, 2018
Renal artery denervation: a lot done and more to do
Sharif F
free

10.4244/EIJ-D-16-01000L Oct 11, 2017
Chemical renal denervation: an effective method to treat resistant hypertension?
Toutouzas K et al
free
Trending articles
95.7

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
65.4

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free
56.1

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
56.1

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
35.45

State-of-the-Art

10.4244/EIJ-D-23-00448 Jan 15, 2024
Coronary spasm and vasomotor dysfunction as a cause of MINOCA
Yaker ZS et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved